Immunic Inc CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the upcoming Phase 2 readout of the CALLIPER trial for vidofludimus calcium in progressive multiple sclerosis (MS). The trial, which includes 467 patients globally, is evaluating the drug’s potential to slow disease progression and provide a much-needed treatment option for progressive MS patients. Vitt confirmed that the trial remains on schedule, with data expected in April. The study aims to assess the drug’s impact on disease progression, brain volume changes, and key biomarkers such as Neurofilament light chain (NfL). The company is particularly focused on addressing the high unmet medical need in non-active secondary progressive MS, a condition with no currently approved treatments. Early biomarker results from the study have been promising. Vitt highlighted that all patient groups experienced around a 20% reduction in NfL levels, a biomarker linked to disease progression. "A lowering of NfL to that extent is likely to be correlated to a decreased risk of disability worsening," he stated, underscoring the potential significance of the upcoming readout. Looking ahead, Immunic is preparing for discussions with regulators and planning a potential Phase 3 trial. Vitt noted that only one Phase 3 study would be required for approval, and positive CALLIPER results could attract interest from major players in the MS treatment space. Stay tuned for further updates. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and enable notifications for future content! #ImmunicInc #MultipleSclerosis #MSResearch #Biotech #CALLIPERTrial #MSAwareness #ClinicalTrials #VidofludimusCalcium #Neuroprotection #Pharma #DrugDevelopment